Merck and Moderna said their personalized neoantigen mRNA vaccine, intismeran autogene, achieved a Phase 3 success in adjuvant melanoma, adding meaningful competition to the neoantigen-vaccine space. The program was tested in combination with Merck’s Keytruda (pembrolizumab), aiming to delay recurrence and reduce distant metastasis after surgical tumor removal. The companies characterized the interim analysis as a statistically significant and clinically meaningful improvement on recurrence-free survival and reported no new safety signals at announcement. While detailed results were not released in the initial coverage, the outcome is positioned as the first randomized Phase 3 readout specifically designed to prove benefit for a personalized neoantigen vaccine. For investors and pipeline planners, the trial result shifts market expectations toward whether personalized mRNA cancer vaccines can scale beyond proof-of-concept and become a repeatable clinical platform rather than a one-off oncology approach.